

# Review of: "Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series"

Yanjun Xu<sup>1</sup>

<sup>1</sup> Harbin Medical University

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

In this study, the authors reviewed the records of patients with BC, and concluded that the HER2 enriched subgroup of patients had the worst prognosis despite receiving targeted therapy. In addition, treatment with trastuzumab increased survival 1.5-fold over that of the HER2-enriched subgroup that did not receive it. The work has certain guiding significance for the treatment of breast cancer. However, I have some concerns as follows:

1. The survival curve should be improved, add P value and 95% confidence interval and median survival time line.
2. The picture is not clear enough, please improve the picture quality.
3. Authors should validate the result that the HER2-enriched subgroup has the worst survival prognosis in an independent breast cancer dataset.
4. The results will be more reliable, if the authors can dissect the specific molecular mechanism of the HER2-enriched subgroup with the worst survival prognosis.